• AG-490 (Tyrphostin B42): Advanced Insights into JAK2/EGFR...

  2026-01-27

  Explore the multifaceted role of AG-490 (Tyrphostin B42), a potent JAK2/EGFR inhibitor, in cancer research and immunopathological state suppression. This in-depth article uniquely analyzes its influence on macrophage polarization and signal transduction, grounded in the latest scientific findings.

• BMS 599626 dihydrochloride: Elevating EGFR/ErbB2 Inhibiti...

  2026-01-26

  This in-depth scenario-driven article demonstrates how BMS 599626 dihydrochloride (SKU B5792) addresses key experimental challenges in cell viability, proliferation, and senescence modeling. Drawing on mechanistic insights and validated preclinical data, the article guides researchers through best practices for reliable EGFR and ErbB2 inhibition, offering actionable advice for robust experimental design and vendor selection.

• Gefitinib (ZD1839): Advancing Tumor Microenvironment Prec...

  2026-01-26

  Explore how Gefitinib (ZD1839), a leading EGFR tyrosine kinase inhibitor, enables precise modulation of the tumor microenvironment for cancer research. Discover unique insights into its anti-angiogenic activity, cell cycle arrest, and application in advanced assembloid models.

• Mifepristone (RU486): Applied Workflows for Oncology & Re...

  2026-01-25

  Mifepristone (RU486) from APExBIO is more than a classic contraceptive agent—it’s a versatile, cell-permeable progesterone receptor antagonist powering breakthroughs in cancer, reproductive biology, and hormone signaling. This guide delivers actionable protocols, troubleshooting tips, and comparative insights to elevate your experimental design and unlock precise modulation of the progesterone receptor signaling pathway.

• SU 5402: Advanced Receptor Tyrosine Kinase Inhibitor for ...

  2026-01-24

  SU 5402 stands out as a potent, selective VEGFR2/FGFR/PDGFR/EGFR inhibitor, enabling precise interrogation of kinase signaling pathways in cancer and neuronal models. From apoptosis assays in multiple myeloma to pathway dissection in human iPSC-derived neurons, SU 5402 offers data-driven workflow enhancements and robust troubleshooting strategies for translational scientists.

• Redefining Ferroptosis Inhibition: Strategic Integration ...

  2026-01-23

  Ferroptosis—a unique, iron-dependent form of regulated cell death—has become a focal point in the investigation of acute organ injuries and therapy-resistant malignancies. This thought-leadership article offers translational researchers a mechanistic deep-dive into ferroptosis regulation, highlights the transformative potential of Liproxstatin-1 HCl as a potent ferroptosis inhibitor, and delivers strategic guidance for integrating new mitochondrial and GPX4 regulatory discoveries into experimental workflows. Moving beyond conventional product summaries, we synthesize cutting-edge evidence and practical frameworks, empowering research teams to deploy Liproxstatin-1 HCl as both a precision tool and a springboard for next-generation translational breakthroughs.

• Gefitinib (ZD1839): Advanced Applications in Tumor Microe...

  2026-01-23

  Explore how Gefitinib (ZD1839), a selective EGFR tyrosine kinase inhibitor, enables groundbreaking research into tumor microenvironment complexity and drug resistance. Discover new strategies for cancer therapy development beyond conventional EGFR inhibition.

• Bazedoxifene: Beyond Osteoporosis—A SERM Targeting IL-6/G...

  2026-01-22

  Explore how Bazedoxifene, a next-generation selective estrogen receptor modulator, not only advances osteoporosis treatment research but also emerges as a novel tool for inhibiting IL-6/GP130 signaling in cancer models. Discover mechanistic insights and translational opportunities for researchers.

• Gefitinib (ZD1839): EGFR Inhibitor Workflows for Advanced...

  2026-01-22

  Leverage Gefitinib (ZD1839) from APExBIO to unlock selective EGFR inhibition in sophisticated tumor assembloid systems and translational cancer workflows. This guide delivers protocol enhancements, troubleshooting strategies, and comparative insights—empowering researchers to address heterogeneity and resistance in next-generation cancer models.

• Gefitinib (ZD1839): Advancing Precision EGFR Inhibition i...

  2026-01-21

  Explore how Gefitinib (ZD1839), a leading EGFR tyrosine kinase inhibitor, is revolutionizing cancer research through advanced modeling of tumor microenvironments. Discover unique scientific insights into selective EGFR inhibition, apoptosis induction, and future applications beyond current assembloid studies.

• Epidermal Growth Factor (EGF), human recombinant: Mechani...

  2026-01-21

  Recombinant human Epidermal Growth Factor (EGF) is a well-characterized growth factor critical for cell proliferation and differentiation. APExBIO’s EGF, expressed in E. coli, offers high purity and validated activity, serving as a robust tool for cell culture and translational research. This dossier details its mechanism, research benchmarks, and practical integration parameters.

• Ganetespib (STA-9090): Potent Triazolone Hsp90 Inhibitor ...

  2026-01-20

  Ganetespib (STA-9090) is a highly potent, triazolone-containing Hsp90 inhibitor that disrupts oncogenic client protein stability through competitive ATP-binding pocket inhibition. It demonstrates nanomolar efficacy across diverse cancer models, making it an essential tool in preclinical oncology research.

• Bazedoxifene: SERM Advancements in Osteoporosis and Cance...

  2026-01-20

  Bazedoxifene is a third-generation selective estrogen receptor modulator (SERM) with high affinity for ERα and ERβ, pivotal in postmenopausal osteoporosis research. Its dual action as an ER antagonist in breast and endometrial tissues and agonist in bone highlights its utility in osteoporosis and emerging anticancer applications.

• SU 5402: Potent FGFR3 and VEGFR2 Inhibitor for Cancer and...

  2026-01-19

  SU 5402 is a selective receptor tyrosine kinase inhibitor used to dissect FGFR3 and VEGFR2 signaling in cancer biology and neuronal models. Its well-characterized inhibition profile, including nanomolar IC50 for VEGFR2 and FGFR1, makes it a benchmark tool for cell cycle arrest and apoptosis studies.

• Ganetespib (STA-9090): Triazolone Hsp90 Inhibitor for Can...

  2026-01-19

  Ganetespib (STA-9090) is a highly potent, non-geldanamycin heat shock protein 90 (Hsp90) inhibitor with a unique triazolone scaffold, validated for rapid oncogenic client protein degradation in diverse cancer models. Its competitive ATP-binding mechanism and nanomolar potency make it a gold standard for studying Hsp90-regulated tumor growth pathways. This article consolidates mechanistic, benchmark, and workflow data to guide researchers in deploying Ganetespib effectively.

15597 records 5/1040 page Previous Next 12345 下5页 Last page